专题:Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

This cluster of papers focuses on the diagnosis, management, and pathogenesis of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. It covers evidence-based guidelines, cellular and molecular mechanisms of fibrosis, therapeutic translation, treatment trials with drugs like pirfenidone and nintedanib, as well as the role of myofibroblasts and epithelial-mesenchymal transition in lung fibrosis.
最新文献
Randomised, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension

article Full Text OpenAlex

Nerandomilast in Patients with Progressive Pulmonary Fibrosis

article Full Text OpenAlex

Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis

article Full Text OpenAlex

First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate

article Full Text OpenAlex

Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: a multicentre observational cohort study

article Full Text OpenAlex

COUNTERPOINT: Should the Progressive Pulmonary Fibrosis Clinical Practice Guideline Be Adopted for Clinical Practice? No

editorial Full Text OpenAlex

POINT: Should the Progressive Pulmonary Fibrosis Clinical Practice Guideline Be Adopted for Clinical Practice? Yes

editorial Full Text OpenAlex

The utility of deeper levels in evaluating transbronchial cryobiopsy specimens for interstitial lung disease

letter Full Text OpenAlex

Polymyxin B-hemoperfusion in patients with acute exacerbation of idiopathic pulmonary fibrosis: a single-center prospective pilot study

article Full Text OpenAlex

Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation

article Full Text OpenAlex

近5年高被引文献
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

article Full Text OpenAlex 1634 FWCI340.399

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

article Full Text OpenAlex 951 FWCI146.749

Fibroblasts: Origins, definitions, and functions in health and disease

review Full Text OpenAlex 683 FWCI26.827

Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation

article Full Text OpenAlex 529 FWCI107.633

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease

article Full Text OpenAlex 440 FWCI66.538

Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis

review Full Text OpenAlex 439 FWCI16.087

ERS clinical practice guidelines on treatment of sarcoidosis

article Full Text OpenAlex 416 FWCI52.73

Persistent Post–COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment

article Full Text OpenAlex 397 FWCI64.036

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

article Full Text OpenAlex 395 FWCI60.534

Global incidence and prevalence of idiopathic pulmonary fibrosis

review Full Text OpenAlex 359 FWCI13.948